These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11553971)

  • 1. The current state of free radicals in Parkinson's disease. Nigral iron as a trigger of oxidative stress.
    Friedman A; Galazka-Friedman J
    Adv Neurol; 2001; 86():137-42. PubMed ID: 11553971
    [No Abstract]   [Full Text] [Related]  

  • 2. [Iron homeostasis and Parkinson's disease].
    Faucheux BA; Hirsch EC
    Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():23-30. PubMed ID: 9827211
    [No Abstract]   [Full Text] [Related]  

  • 3. What process causes nigral cell death in Parkinson's disease?
    Jenner P
    Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
    Floor E
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):709-20. PubMed ID: 10875434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pesticides and metals induced Parkinson's disease: involvement of free radicals and oxidative stress.
    Singh C; Ahmad I; Kumar A
    Cell Mol Biol (Noisy-le-grand); 2007 May; 53(5):19-28. PubMed ID: 17543230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free radical and nitric oxide toxicity in Parkinson's disease.
    Przedborski S; Jackson-Lewis V; Vila M; Wu DC; Teismann P; Tieu K; Choi DK; Cohen O
    Adv Neurol; 2003; 91():83-94. PubMed ID: 12442666
    [No Abstract]   [Full Text] [Related]  

  • 7. [Etiology and pathogenesis of parkinson's disease].
    Mizuno Y; Ikebe S; Mochizuki H; Matumine H; Kondo T
    No To Shinkei; 1996 Jan; 48(1):5-17. PubMed ID: 8679319
    [No Abstract]   [Full Text] [Related]  

  • 8. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An introduction to the free radical hypothesis in Parkinson's disease.
    Olanow CW
    Ann Neurol; 1992; 32 Suppl():S2-9. PubMed ID: 1510376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron as a cause of Parkinson disease - a myth or a well established hypothesis?
    Friedman A; Galazka-Friedman J; Koziorowski D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S212-4. PubMed ID: 20082993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Free radicals and ailing proteins--the culprits behind Parkinson disease?].
    Smith R; Lotharius J; Brundin P
    Lakartidningen; 2003 Apr; 100(15):1324-6, 1329-30. PubMed ID: 12739402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
    J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease.
    Fitzmaurice PS; Ang L; Guttman M; Rajput AH; Furukawa Y; Kish SJ
    Mov Disord; 2003 Sep; 18(9):969-76. PubMed ID: 14502663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astrocyte mitochondria: a substrate for iron deposition in the aging rat substantia nigra.
    Schipper HM; Vininsky R; Brull R; Small L; Brawer JR
    Exp Neurol; 1998 Aug; 152(2):188-96. PubMed ID: 9710517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control.
    Koziorowski D; Friedman A; Arosio P; Santambrogio P; Dziewulska D
    Parkinsonism Relat Disord; 2007 May; 13(4):214-8. PubMed ID: 17275395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifications of the iron-neuromelanin system in Parkinson's disease.
    Fasano M; Bergamasco B; Lopiano L
    J Neurochem; 2006 Feb; 96(4):909-16. PubMed ID: 16417570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
    Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
    Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.
    Mandel S; Grunblatt E; Riederer P; Amariglio N; Jacob-Hirsch J; Rechavi G; Youdim MB
    Ann N Y Acad Sci; 2005 Aug; 1053():356-75. PubMed ID: 16179542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pumping iron in Parkinson's disease.
    Bonn D
    Lancet; 1996 Jun; 347(9015):1614. PubMed ID: 8667877
    [No Abstract]   [Full Text] [Related]  

  • 20. Iron, free radicals, and oxidative injury.
    McCord JM
    Semin Hematol; 1998 Jan; 35(1):5-12. PubMed ID: 9460805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.